What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Denecimig demonstrated substantial reductions in treated-bleed annualized bleeding rates (ABRs) compared to on-demand treatment and prior factor prophylaxis in phase 3 trials. However, there is no direct comparative data versus emicizumab or other active non-factor prophylaxis, limiting the ability to claim superiority over these treatments.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-utility analysis, ICER, or economic model was identified for denecimig. Therefore, cost-effectiveness cannot be assessed.
Is there quality-of-life evidence payers weigh? — Quality of life
Partial data on HRQoL instruments are available, but no public analysis linked these measures to utility values or demonstrated blinded comparative responsiveness. The evidence suggests minimal or mixed impact on HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Denecimig showed acceptable short-term tolerability with no thromboembolic events or clinical evidence of neutralizing antibodies reported. However, the evidence is limited by open-label ascertainment and modest exposure.
Was the drug compared against what payers expect? — Comparator Selection
The trials did not include emicizumab or other relevant non-factor prophylaxis as comparators, which are important active SOCs. The comparator selection is suboptimal for contemporary reimbursement decisions.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a broad range of patients, including children, adolescents, adults, and those with inhibitors. However, limited female participation and underreported race/ethnicity limit equity assessment.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Denecimig’s flexible dosing aligns well with heterogeneous practice needs, and it was administered with a prefilled pen, suggesting minor, manageable adjustments to existing care pathways.
Are the wider system costs understood? — Resource Use and Cost Implications
No budget-impact or resource information is presented, making it impossible to assess resource use and cost implications.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on randomized phase 3 trials with prespecified endpoints. However, the absence of an active non-factor comparator and reliance on sponsor-supported congress presentations for some data limit the robustness.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
High uncertainty exists due to the lack of direct comparative data versus emicizumab, rare thrombosis, and long-term outcomes. The absence of an economic model further contributes to uncertainty.
